A detailed history of Enterprise Bank & Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Enterprise Bank & Trust CO holds 4,104 shares of BMY stock, worth $241,602. This represents 0.07% of its overall portfolio holdings.

Number of Shares
4,104
Holding current value
$241,602
% of portfolio
0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$39.66 - $51.75 $162,764 - $212,382
4,104 New
4,104 $212,000
Q1 2024

Apr 10, 2024

SELL
$47.98 - $54.4 $35,985 - $40,800
-750 Reduced 14.8%
4,316 $234,000
Q4 2023

Jan 09, 2024

BUY
$48.48 - $57.85 $33,160 - $39,569
684 Added 15.61%
5,066 $259,000
Q3 2023

Oct 16, 2023

BUY
$57.89 - $64.73 $21,071 - $23,561
364 Added 9.06%
4,382 $254,000
Q2 2023

Jul 06, 2023

BUY
$63.71 - $70.74 $255,986 - $284,233
4,018 New
4,018 $256,000
Q2 2021

Jul 06, 2021

SELL
$61.91 - $67.42 $229,686 - $250,128
-3,710 Closed
0 $0
Q1 2021

Apr 15, 2021

SELL
$59.34 - $66.74 $39,757 - $44,715
-670 Reduced 15.3%
3,710 $234,000
Q4 2020

Jan 05, 2021

SELL
$57.74 - $65.43 $8,661 - $9,814
-150 Reduced 3.31%
4,380 $272,000
Q3 2020

Oct 16, 2020

SELL
$57.43 - $63.64 $70,122 - $77,704
-1,221 Reduced 21.23%
4,530 $273,000
Q2 2020

Jul 10, 2020

BUY
$54.82 - $64.09 $11,512 - $13,458
210 Added 3.79%
5,751 $338,000
Q1 2020

Apr 07, 2020

SELL
$46.4 - $67.43 $18,513 - $26,904
-399 Reduced 6.72%
5,541 $309,000
Q4 2019

Jan 07, 2020

BUY
$49.21 - $64.19 $63,973 - $83,447
1,300 Added 28.02%
5,940 $381,000
Q2 2019

Jul 12, 2019

SELL
$44.62 - $49.34 $25,210 - $27,877
-565 Reduced 10.85%
4,640 $210,000
Q1 2019

Apr 24, 2019

BUY
$45.12 - $53.8 $234,849 - $280,029
5,205 New
5,205 $248,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Enterprise Bank & Trust CO Portfolio

Follow Enterprise Bank & Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Enterprise Bank & Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Enterprise Bank & Trust CO with notifications on news.